{
  "docId": "019de070-7de1-7343-8d2f-5d51a9877c50",
  "docSlug": "ff3158b4501b6094038126272ca46097",
  "documentTitle": "BioAtla | IPO Presentation Deck | 31 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 30,
  "pageCount": 31,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-7de1-7343-8d2f-5d51a9877c50/30",
  "deckHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50",
  "deckJsonHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50.json",
  "deckAnchorHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.8,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "list",
      "text": "Innovative CAB technology platform, with clinically-validated antibodies, that conditionally activate at optimal exposure levels, exhibit high potency, and possess ideal safety profiles",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56880743-f466-45bd-bd5c-86c8ef3ddf9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.8,
        "x": 0.15,
        "y": 0.65
      },
      "kind": "list",
      "text": "Talented and experienced management team, with a strong track record and over 20 years of experience on average with leading biopharmaceutical companies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "653ed99f-664a-4488-85b7-064f06d655d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.8,
        "x": 0.15,
        "y": 0.5
      },
      "kind": "list",
      "text": "Strong intellectual property foundation that provides worldwide coverage and multiple diversified patents for each product",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6efba577-b65e-419e-9b5a-be647ccdab38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.8,
        "x": 0.15,
        "y": 0.8
      },
      "kind": "list",
      "text": "Strong financial support through a global collaboration with BeiGene and backing of reputable investors such as Pfizer Ventures, Soleus Capital, and HBM Healthcare Investments",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "850d194a-9f75-4904-a1a9-01f3d6437897",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.8,
        "x": 0.15,
        "y": 0.35
      },
      "kind": "list",
      "text": "Multiple clinical assets demonstrating differentiated CAB technology and strong results for challenging targets, leading to novel therapeutics that can fulfill previously unmet patient needs, and resulting in a broad and diverse pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8847ebf4-852f-4fb1-9636-579cb63eccd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "BioAtla is well positioned to develop a strong franchise of CAB-enabled treatments",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab036702-f023-4fd1-9aa9-2c35d89d980d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Summary and Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ac25355-d556-408e-9dd9-f7d250a0ee45",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "426c9e34-7091-4e35-85fe-e86bd0b5fb99",
      "evidence": "The document implies the cost of inaction by presenting the potential benefits of BioAtla's technology.",
      "position": 0,
      "objective": "What is the cost of not adopting BioAtla's technology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}